Table 1 Summary of substitutions associated with resistance to nucleoside and non-nucleoside NS5B inhibitors [26,27,28]
Position | RAS | Genotype | Drug |
|---|---|---|---|
159 | F | 1a | SOF |
237 | G | 1a | SOF |
282 | R/ T | 1a | SOF |
316 | F | 1a | SOF |
320 | F | 1a | SOF |
321 | A | 1a | SOF |
159 | F | 1b | SOF |
282 | G/T | 1b | SOF |
316 | F/H/N | 1b | SOF |
321 | I | 1b | SOF |
314 | H | 1a | DSV |
316 | Y | 1a | DSV |
414 | T/V | 1a | DSV |
448 | C/H | 1a | DSV |
553 | I /V | 1a | DSV |
554 | S | 1a | DSV |
556 | G/N/R | 1a | DSV |
558 | R | 1a | DSV |
559 | G | 1a | DSV |
316 | Y/ H /N | 1b | DSV |
368 | T | 1b | DSV |
414 | I | 1b | DSV |
445 | F | 1b | DSV |
448 | C | 1b | DSV |
553 | V | 1b | DSV |
556 | G | 1b | DSV |
559 | G/N | 1b | DSV |
421 | V | 1a | BCV |
495 | L/S | 1a | BCV |
499 | A/any | 1b | DLV |